Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
December 23, 2021
Artificial intelligence analysis of three-dimensional imaging data derives factors associated with postoperative recurrence in patients with radiologically solid-predominant small-sized lung cancers
Yujin Kudo, Yoshihisa Shimada, Jun Matsubayashi, et al.
Heart and Vessels
|
April 24, 2016
The efficacy of a multidisciplinary team approach in critical limb ischemia
Hiroshi Suzuki, Atsuo Maeda, Hideyuki Maezawa, et al.
Oncotargets and Therapy
|
October 2, 2018
A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
Teppei Sugano, Masahiro Seike, Rintaro Noro, et al.
Molecular and Clinical Oncology
|
March 7, 2022
Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
Akiko Takahashi, Rintaro Noro, Natsuki Takano, et al.
JTO Clinical and Research Reports
|
April 22, 2024
Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in <i>EGFR</i>-Mutant Lung Cancer
Takehiro Tozuka, Rintaro Noro, Keisuke Yoshida, et al.
Journal of Thoracic Disease
|
March 14, 2025
Efficacy and safety of pleurodesis for lung cancer patients with interstitial lung disease
Hirokazu Iso, Akihiko Miyanaga, Yozo Sato, et al.
Cancer Medicine
|
February 22, 2023
Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01)
Susumu Takeuchi, Kaoru Kubota, Shunichi Sugawara, et al.
Oncotargets and Therapy
|
September 22, 2018
Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
Takehiro Tozuka, Masahiro Seike, Yuji Minegishi, et al.
Anticancer Research
|
December 3, 2024
Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of <i>ABCB1</i> in Non-small Cell Lung Cancer
Anna Hayashi, Koichiro Kamio, Akihiko Miyanaga, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 7, 2023
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
Satoshi Watanabe, Naoki Furuya, Atsushi Nakamura, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
December 23, 2021
Artificial intelligence analysis of three-dimensional imaging data derives factors associated with postoperative recurrence in patients with radiologically solid-predominant small-sized lung cancers
Yujin Kudo, Yoshihisa Shimada, Jun Matsubayashi, et al.
Heart and Vessels
|
April 24, 2016
The efficacy of a multidisciplinary team approach in critical limb ischemia
Hiroshi Suzuki, Atsuo Maeda, Hideyuki Maezawa, et al.
Oncotargets and Therapy
|
October 2, 2018
A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
Teppei Sugano, Masahiro Seike, Rintaro Noro, et al.
Molecular and Clinical Oncology
|
March 7, 2022
Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
Akiko Takahashi, Rintaro Noro, Natsuki Takano, et al.
JTO Clinical and Research Reports
|
April 22, 2024
Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in <i>EGFR</i>-Mutant Lung Cancer
Takehiro Tozuka, Rintaro Noro, Keisuke Yoshida, et al.
Journal of Thoracic Disease
|
March 14, 2025
Efficacy and safety of pleurodesis for lung cancer patients with interstitial lung disease
Hirokazu Iso, Akihiko Miyanaga, Yozo Sato, et al.
Cancer Medicine
|
February 22, 2023
Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01)
Susumu Takeuchi, Kaoru Kubota, Shunichi Sugawara, et al.
Oncotargets and Therapy
|
September 22, 2018
Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
Takehiro Tozuka, Masahiro Seike, Yuji Minegishi, et al.
Anticancer Research
|
December 3, 2024
Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of <i>ABCB1</i> in Non-small Cell Lung Cancer
Anna Hayashi, Koichiro Kamio, Akihiko Miyanaga, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 7, 2023
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
Satoshi Watanabe, Naoki Furuya, Atsushi Nakamura, et al.
Page
of 7